
Biomerica, Inc.
BMRANASDAQHealthcareMedical - Devices
Previous close
$1.61
+$0.025 · +1.58%
BMRA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
36
Expensive
Momentum
19
Strong Down
Sentiment
53
Mixed
Risk resilience
38
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBiomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Zackary S. Irani
- Listed since
- Sep 7, 1984
- Employees
- 54
Market position
Day range
Current $1.61
52-week range
Current $1.61
- Open
- $1.575
- Previous close
- $1.585
- Volume
- 9.88K
- 0.72× average
- Average volume
- 13.67K
- Average daily volume
- Market cap
- 4.98M USD
- Beta
- 0.31
- Market reference 1
- 50-day average
- $1.6816
- -4.26% below average
- 200-day average
- $2.1476
- -25.03% below average
Financials
Financial snapshot
Latest / TTMFinancial health
- Altman Z-score
- -15.39
- Piotroski F-score
- 3 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.31M USD | 5.42M USD | 5.34M USD | 18.87M USD | 7.2M USD |
| Cost of goods sold | 4.81M USD | 4.8M USD | 4.89M USD | 15.89M USD | 6.83M USD |
| Gross profit | 498K USD | 611K USD | 446K USD | 2.98M USD | 366.29K USD |
| Research and development | 1.02M USD | 1.49M USD | 1.58M USD | 1.81M USD | 2.19M USD |
| Selling, general, and administrative | 4.61M USD | 5.49M USD | 6.09M USD | 5.7M USD | 5.67M USD |
| Operating expenses | 5.64M USD | 6.98M USD | 7.67M USD | 7.51M USD | 7.87M USD |
| Interest income | 165K USD | 431K USD | 133K USD | 27K USD | 66.86K USD |
| Interest expense | — | — | — | — | 367 USD |
| Depreciation and amortization | 400K USD | 374K USD | 351K USD | 594.82K USD | 375.86K USD |
| Operating income | −5.14M USD | −6.37M USD | −7.22M USD | −4.53M USD | −7.5M USD |
| Net income | −4.97M USD | −5.98M USD | −7.14M USD | −4.53M USD | −7.45M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -2.16
- FY2025
- Latest fiscal-year revenue
- 5.31M USD
- FY2025 · -1.92% year over year
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
BMRA peers
ETFs holding BMRA
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research BMRAresearch.disclaimer






